Clinical Trials Logo

T2DM (Type 2 Diabetes Mellitus) clinical trials

View clinical trials related to T2DM (Type 2 Diabetes Mellitus).

Filter by:

NCT ID: NCT06293417 Not yet recruiting - Dyslipidemias Clinical Trials

To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM

ENSEMBLE
Start date: March 1, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to assess in the long term efficacy and safety of ezefeno. The primary endpoint are: - major adverse cardiovascular events within 48 months of the trial duration - microvascular events within 48 months of the trial duration

NCT ID: NCT06254274 Recruiting - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

A Study of RAY1225 in Participants With Type 2 Diabetes

Start date: February 26, 2024
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

NCT ID: NCT06141980 Not yet recruiting - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

Start date: December 2023
Phase: Phase 3
Study type: Interventional

The subjects, having voluntarily agreed to participate in the clinical trial and provided informed consent, will undergo screening tests. During Visit 1 (Screening), subjects meeting the inclusion/exclusion criteria will go through an 8-week stabilization period. At Visit 1-1, central laboratory tests will be conducted. If the test results meet the criteria for Visit 2 (Enrollment Visit), the subject will be eligible to participate in the clinical trial. The subjects will receive the investigational drug (DWP16001 0.3 mg) once a day for 52 weeks. They will visit the clinical trial site at weeks 8, 16, 24, 38, and 52 for safety and efficacy assessments during the 52-week treatment period.

NCT ID: NCT06094491 Not yet recruiting - Obesity Clinical Trials

Virtual Diabetes Group Visits Across Health Systems

VIDA
Start date: November 2023
Phase: N/A
Study type: Interventional

The purpose of this project is to evaluate the effectiveness of a virtual diabetes group visits on patients with type 2 diabetes mellitus (T2DM).

NCT ID: NCT06055582 Completed - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

To Study the Effects of Mango Ingestion in T2DM and Non-diabetic Subjects.

Start date: February 11, 2022
Phase: N/A
Study type: Interventional

T2DM patient will be recruited from endocrine OPD 1. Clinical History and Examination: 1. General Physical Examination: - Height (cm) - weight (kg) - BMI (kg/m2) - Blood Pressure (mmHg) 2. Anthropometry: Circumferences and skinfold thickness will be recorded for the patients in the following manner. Circumferences: - Waist circumference (cm) - Hip circumference (cm) - Mid-arm circumference (cm) - Mid-thigh circumference (cm) 3. Skin fold thickness: Skin fold thickness will be measured by using (LANGE skin fold calipers) (to nearest of 1 mm) at the following sites - Biceps (mm) - Triceps (mm) - Thigh (mm) - Calf (mm) - Sub scapular (mm) - Supra-iliac (mm) - Anterior axillary fold. (mm) 2. Biochemical Test: The biochemical analysis will be done using ELISA kit or commercially available kits - Blood glucose (mg/dL) - HbA1c (%) - Serum insulin (μIU/mL) - Total Cholestrol (mg/dl) - Triglyceride (mg/dl) - Fructosamine (umol/L) - Adiponectin (µg/ml) -- HOMA-IR 3. Body Composition Analysis (TANITA)

NCT ID: NCT05983289 Completed - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

Single Escalating Dose Study Of HSK7653 In Healthy Subjects

Start date: May 8, 2018
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of single dose of HSK7653 tablets in healthy adult subjects, and to identify the metabolites of HSK7653 in healthy adult subjects

NCT ID: NCT05943886 Completed - Obesity Clinical Trials

A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects

Start date: August 11, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, double-blind, placebo-controlled, escalating single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC88473 injection in healthy subjects, obese subjects and subjects with type 2 diabetes mellitus (T2DM).

NCT ID: NCT05469659 Recruiting - Metformin Clinical Trials

Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)

TRUTH-DKD
Start date: September 22, 2021
Phase: Phase 2
Study type: Interventional

This multicenter, randomized, open-label, controlled study will assess the efficacy of the SGLT2 inhibitor tofogliflozin on Urine Albumin-to-Creatinine Ratio (UACR) compared to metformin in patients with type 2 diabetes with chronic kidney disease (CKD).

NCT ID: NCT05376969 Completed - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin

ENHANCE-MEXT
Start date: May 25, 2021
Phase: Phase 3
Study type: Interventional

A Multi-center, Open-label, Extension study to Evaluate the long term Safety and Efficacy of DWP16001 add-on to metformin in Patients with type 2 diabetes mellitus inadequately controlled on metformin

NCT ID: NCT05376930 Completed - Clinical trials for T2DM (Type 2 Diabetes Mellitus)

Study to Evaluate the Long Term Safety and Efficacy of DWP16001 Compared to Placebo in the Treatment of T2DM.

Start date: September 16, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is evaluate the long term safety and efficacy of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.